The Four Classical Indirect-Response Model Types

Why Classify Indirect-Response Models?

A measured response may change because a drug alters how quickly that response is produced, how quickly it is removed, or both. These mechanisms can give the same direction of change but imply different rate balances. The four classical indirect-response types organize the simplest possibilities: the drug stimulates or inhibits either response production or response loss.

The response variable \(R(t)\) might represent the amount or concentration of a protein or another measurable quantity. In each model, production and loss continue to operate over time; the drug modifies one of those rates. The response therefore does not generally jump to its new value as soon as drug exposure changes. Its trajectory reflects turnover.

Baseline Turnover and Model Assumptions

Let \(k_{\mathrm{in}}\) be the constant response production rate, with units of response per unit time, and let \(k_{\mathrm{out}}\) be the first-order loss-rate constant, with units of inverse time. Without drug, the balance equation is

Assume \(k_{\mathrm{in}}>0\), \(k_{\mathrm{out}}>0\), and that the untreated response has reached steady state. Setting the derivative to zero gives the baseline response \(R_0\):

For the four drug-effect equations below, suppose drug exposure \(C\) is held constant, so the effect functions do not change during the calculation. Let \(I(C)\) denote a fractional inhibition, with \(0\leq I(C)\leq 1\), and let \(S(C)\) denote a nonnegative fractional stimulation, with \(S(C)\geq 0\). Both are dimensionless. This notation describes the size of an effect without specifying a particular concentration-effect function.

The basic assumptions are that production and loss are represented by the stated rates, loss is first-order in \(R\), and the drug modifies only the rate indicated by its model type. The drug effect is treated as constant when deriving a drug-treated steady state. These are useful simplifying assumptions, not guarantees that a biological system has only one response pool or one mechanism.

The Four Rate Equations

Each model retains the same production-loss structure and changes one rate. The effect function multiplies the production rate in Types I and II, and the loss-rate constant in Types III and IV.

In every equation, \(I\) and \(S\) stand for the values of \(I(C)\) and \(S(C)\) at the fixed exposure. A zero effect (\(I=0\) or \(S=0\)) recovers the untreated equation and \(R_0\). Type III requires special attention: complete inhibition of loss, \(I=1\), removes the loss term, so the response does not approach a finite steady state under continued positive production.

Deriving the Steady-State Directions

The direction of the steady-state change follows from setting the appropriate rate equation to zero. For Type I, the drug reduces the input while leaving loss unchanged:

Because \(0\leq I\leq 1\), \(0\leq 1-I\leq 1\), and therefore \(R_{\mathrm{ss}}\leq R_0\). Production inhibition lowers or, at complete inhibition, brings the steady-state response to zero.

For Type II, production is multiplied by \(1+S\):

For Type III, solving for \(R_{\mathrm{ss}}\) requires a positive effective loss-rate constant, \(k_{\mathrm{out}}(1-I)>0\), or equivalently \(I<1\):

Thus, inhibiting loss raises the steady state when the inhibition is partial. For Type IV, loss is multiplied by \(1+S\):

Stimulating loss lowers the steady state. These inequalities describe steady-state direction, not how quickly the response changes or whether two models produce the same time course.

This stability result follows directly by defining the deviation \(e(t)=R(t)-R_{\mathrm{ss}}\). Since \(a-bR_{\mathrm{ss}}=0\), subtracting the steady-state equation from the dynamic equation gives

For \(b>0\), the exponential factor tends to zero, so \(R(t)\) approaches \(R_{\mathrm{ss}}\). In Type III at \(I=1\), \(b=0\), and the equation instead becomes \(\frac{dR}{dt}=k_{\mathrm{in}}\); positive production causes linear accumulation rather than convergence to a finite equilibrium.

Worked Examples

Interpreting Time Courses and Choosing a Model

The four types form two pairs with matching steady-state directions: Types I and IV lower the response, while Types II and III raise it. A steady-state increase alone cannot distinguish production stimulation from loss inhibition. Similarly, a decrease alone cannot distinguish production inhibition from loss stimulation. The rate equation identifies the proposed mechanism; the direction of change by itself does not.

For a constant effect, the coefficient of \(R\) also affects the response time course. Types I and II retain the untreated loss-rate constant \(k_{\mathrm{out}}\), so deviations from their new steady states decay with that rate. Types III and IV change the effective loss rate to \(k_{\mathrm{out}}(1-I)\) or \(k_{\mathrm{out}}(1+S)\), respectively. Partial loss inhibition slows the decay toward equilibrium; loss stimulation speeds it up. A time course can therefore provide information beyond the final response level, although noisy or sparse measurements may not identify the mechanism uniquely.

These models are alternatives to an immediate direct-response representation, in which the measured response is specified as changing directly with drug effect. An indirect-response model is appropriate when there is a reason to represent the response as a pool governed by production and loss. If the scientific question requires separate mRNA and protein states or explicitly represented intermediate steps, a coupled state-variable model may be more appropriate than compressing the biology into one response equation.

Diagnostics, Pitfalls, and Limitations

Compare the fitted or hypothesized rate equation with the observations and biological assumptions. A response that changes before the proposed production or loss process could plausibly act may challenge the model. Failure to approach a plateau during the observation period does not by itself refute an indirect-response mechanism: the turnover time may be long. Conversely, a plateau is not proof of a particular one of the four types.

• Check the baseline balance. If the assumed untreated steady state is \(R_0\), the parameters should satisfy \(k_{\mathrm{in}}=k_{\mathrm{out}}R_0\).
• Check units. \(k_{\mathrm{in}}\) must have units of response per time; \(k_{\mathrm{out}}\) must have units of inverse time; and \(I\) and \(S\) are dimensionless.
• Check Type III admissibility. For a finite steady state, \(I<1\). As \(I\) approaches one, the predicted steady state grows without bound, which may signal that the simple model is being extrapolated beyond a plausible range.
• Check the intervention and exposure assumption. A changing drug concentration means \(I(C)\) or \(S(C)\) may change over time; the constant-effect steady-state calculation does not describe that entire trajectory.
• Check for unmodeled processes. Feedback, multiple response pools, time-varying baseline production, or non-first-order loss may make the single-state equations inadequate.

A common mistake is to infer the affected rate from the response direction: “The response rose, so the drug must stimulate production.” That conclusion is not justified, because inhibiting loss also raises the steady state. The correction is to treat the four mechanisms as competing rate hypotheses and use the model assumptions and time-course evidence, not direction alone, to distinguish them.

The classical equations are deliberately compact. They do not specify how \(I(C)\) or \(S(C)\) depends on concentration, prove that only one rate is drug-sensitive, or account automatically for feedback and capacity limits. Their main value is to make the production-loss bookkeeping explicit and to provide testable predictions about steady-state direction and turnover.